Opinion|Videos|September 26, 2024
Safety and Efficacy of Janus Kinase Inhibitors
Panelists discuss how the findings from the ORAL Surveillance study regarding cardiovascular and cancer risks associated with tofacitinib have influenced perceptions of JAK inhibitors, emphasizing the need to balance safety concerns with their efficacy in managing rheumatoid arthritis.
Advertisement
Episodes in this series
Video content above is prompted by the following:
Results from the 2021 ORAL Surveillance study showed the Janus kinase inhibitor (JAKi) tofacitinib was associated with a cardiovascular and cancer risk.
- Can you describe concerns and misperceptions that ensued from results of the ORAL Surveillance study? What were the limitations of the study?
- Can you please share how you weigh JAKi safety concerns with their efficacy outcomes?
- In your clinical observations, what role have JAKis played in helping patients with rheumatoid arthritis achieve remission?
Advertisement
Related to this article
The EC approved upadacitinib for active polyarticular JIA in children 2 years and older, based on phase 1 SELECT-YOUTH efficacy and safety data.
August 2026 rheumatology highlights include FDA approval of brepocitinib for dermatomyositis and garetosmab-grts for FOP, and new trial data.
In RA-BRIDGE and RA-BRANCH, baricitinib failed to demonstrate VTE noninferiority in patients with RA enriched for thromboembolic risk factors.
A Phase 2a basket trial produced ACR50 responses in 71% of refractory RA patients at 6 months.
Advertisement
Advertisement